ACA
KRYS icon

Avoro Capital Advisors’s Krystal Biotech KRYS Stock Holding History

Avoro Capital Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07B Hold
2,888,888
– – 9.64% 3
2026
Q1 		$746M Hold
2,888,888
– – 7.34% 4
2025
Q4 		$712M Buy
2,888,888
+111,111
+4% +$23.4M 7% 5
2025
Q3 		$490M Buy
2,777,777
+117,777
+4% +$17.6M 6.34% 5
2025
Q2 		$366M Sell
2,660,000
-71,000
-3% -$10.4M 6.4% 5
2025
Q1 		$492M Buy
2,731,000
+102,178
+4% +$17.2M 7.69% 5
2024
Q4 		$412M Buy
2,628,822
+6,600
+0.3% +$1.17M 5.83% 5
2024
Q3 		$477M Buy
2,622,222
+189,222
+8% +$36.5M 6.96% 4
2024
Q2 		$447M Sell
2,433,000
-122,555
-5% -$20.6M 5.95% 6
2024
Q1 		$455M Sell
2,555,555
-10,000
-0.4% -$1.39M 5.3% 7
2023
Q4 		$318M Hold
2,565,555
– – 4.4% 11
2023
Q3 		$298M Buy
2,565,555
+4,744
+0.2% +$579K 4.64% 10
2023
Q2 		$301M Buy
2,560,811
+810,811
+46% +$82.8M 4.08% 12
2023
Q1 		$140M Buy
1,750,000
+340,000
+24% +$26.7M 2.08% 15
2022
Q4 		$112M Buy
1,410,000
+135,000
+11% +$10M 1.67% 15
2022
Q3 		$88.9M Buy
1,275,000
+200,000
+19% +$14.4M 1.64% 16
2022
Q2 		$70.6M Buy
1,075,000
+70,000
+7% +$4.35M 1.39% 16
2022
Q1 		$66.9M Buy
1,005,000
+530,000
+112% +$33.1M 1.22% 18
2021
Q4 		$33.2M Buy
+475,000
New +$27.6M 0.57% 30

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Avoro Capital Advisors's KRYS Position: Q2 2026 in Review

Avoro Capital Advisors held its Krystal Biotech (KRYS) position steady in Q2 2026 at 2,888,888 shares worth $1.07B. The position accounts for 9.64% of the portfolio, ranked #3.

Avoro Capital Advisors first reported a position in KRYS in Q4 2021 and has held it in 19 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Avoro Capital Advisors held 2,888,888 shares of Krystal Biotech worth $1.07B as of Q2 2026.
  • Avoro Capital Advisors left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up 9.64% of Avoro Capital Advisors's portfolio in Q2 2026, its #3 holding.
  • Avoro Capital Advisors first reported a position in Krystal Biotech in Q4 2021 and has held it in 19 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.